Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: A phase ii trial

Anticancer Research

Volumn 35, Issue 1, 2015, Pages 517-522

  Pircher, Magdalena ^a   Mlineritsch, Brigitte ^a   Fridrik, Michael A ^b   Dittrich, Christian ^c   Lang, Alois ^d   Petru, Edgar ^e   Weltermann, Ansgar ^f   Thaler, Josef ^g   Hufnagl, Clemens ^a   Gampenrieder, Simon Peter ^a   Rinnerthaler, Gabriel ^a   Ressler, Sigrun ^a   Ulmer, Hanno ^h   Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d General Hospital of Rankweil   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f Second Department of Medicine   (Austria)

^g Hospital Wels Grieskirchen   (Austria)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Her2 positive; Lapatinib; Metastatic breast cancer; Pegylated liposomal doxorubicin

Indexed keywords

CAPECITABINE; DOXORUBICIN; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ADVANCED HER2 POSITIVE BREAST CANCER; ANEMIA; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; HEART FAILURE; HUMAN; INFECTION; INFECTIOUS PNEUMONIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SKIN DISEASE; THROMBOCYTOPENIA; VOMITING; ADULT; AGED; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84920492813     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Meric F, Hung MC, Hortobagyi GN and Hunt KK: HER2/neu in the management of invasive breast cancer. Journal of the American College of Surgeons 194: 488-501, 2002.
2. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. The New England journal of medicine 357: 39-51, 2007.
3. Damodaran S and Olson EM: Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. Hosp Pract (1995) 40: 7-15, 2012.
4. Alroy I and Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS letters 410: 83-86, 1997.
5. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S and Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine 355: 2733-2743, 2006.
6. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J and O'Shaughnessy J: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30: 2585-2592, 2012.
7. Slamon DJ and Press MF: Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. Journal of the National Cancer Institute 101: 615-618, 2009.
8. Brower V: Cardiotoxicity Debated for Anthracyclines and Trastuzumab in Breast Cancer. Journal of the National Cancer Institute 105: 835-836, 2013.
9. Rayson D, Suter TM, Jackisch C, van der Vegt S, Bermejo B, van den Bosch J, Vivanco GL, van Gent AM, Wildiers H, Torres A, Provencher L, Temizkan M, Chirgwin J, Canon JL, Ferrandina G, Srinivasan S, Zhang L and Richel DJ: Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 23: 1780-1788, 2012.
10. Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR and Panasci L: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24: 2773-2778, 2006.
11. Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P, Russ G, Rass C and Greil R: Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 32: 18-24, 2009.
12. Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC and Steger GG: Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. British journal of cancer 106: 25-31, 2012.
13. Bachelot T, Le Rhun E, Labidi-Gally I, Heudel P, Gilabert M, Bonneterre J, Pierga JY and Goncalves A: Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies. Bulletin du cancer 100: 7-14, 2013.
14. Green SJ and Dahlberg S: Planned versus attained design in phase II clinical trials. Statistics in medicine 11: 853-862, 1992.
15. Agresti A and Coull BA: Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions. The American Statistician 52: 119-126, 1998.
16. Fiegl M, Mlineritsch B, Hubalek M, Bartsch R, Pluschnig U and Steger GG: Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial. BMC Cancer 11: 373, 2011.
17. Pereira CB, Leal MF, de Souza CR, Montenegro RC, Rey JA, Carvalho AA, Assumpcao PP, Khayat AS, Pinto GR, Demachki S, de Arruda Cardoso Smith M and Burbano RR: Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. PLoS One 8: e60576, 2013.
18. Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, Pierga JY, Marty M, de Cremoux P, Spyratos F and Bieche I: Outcome impact of PIK3CA mutations in HER2- positive breast cancer patients treated with trastuzumab. British journal of cancer 108: 1807-1809, 2013.
19. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM and Pusztai L: Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast cancer research and treatment 134: 333-343, 2012.
20. Ang DC, Warrick AL, Shilling A, Beadling C, Corless CL and Troxell ML: Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2013.
21. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A and Wardley AM: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. British journal of cancer 91: 639-643, 2004.
22. Swaby XPVSBZRAAFECRPMDSSR: CEREBEL (EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ Metastatic Breast Cancer (MBC), treated with Lapatinib plus Capecitabine (LC) versus Trastuzumab plus Capecitabine (TC). ESMO 2012.
23. Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.
24. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S and Blackwell K: Trastuzumab emtansine for HER2- positive advanced breast cancer. The New England journal of medicine 367: 1783-1791, 2012.